The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy

Oncogene

Volumn 31, Issue 27, 2012, Pages 3254-3264

  Kidoya, H ^a   Kunii, N ^b   Naito, H ^a   Muramatsu, F ^a   Okamoto, Y ^b   Nakayama, T ^b   Takakura, N ^a  

^a OSAKA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

apelin APJ; immune therapy; tumor angiogenesis; vascular maturation; vascular normalization

Indexed keywords

APELIN; APELIN RECEPTOR; DENDRITIC CELL VACCINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; INVARIANT NATURAL KILLER T CELL; LYMPHOCYTIC INFILTRATION; MATURATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD VESSELS; BONE MARROW CELLS; CELL PROLIFERATION; CELL TRANSPLANTATION; COMBINED MODALITY THERAPY; DENDRITIC CELLS; ENDOTHELIAL CELLS; GALACTOSYLCERAMIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NATURAL KILLER T-CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, G-PROTEIN-COUPLED; TREATMENT OUTCOME;

EID: 84863719408     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.489     Document Type: Article

References (52)

1. Bergers G, Benjamin LE. (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410. (Pubitemid 37328844)
2. Bottaro DP, Liotta LA. (2003). Cancer: out of air is not out of action. Nature 423: 593-595. (Pubitemid 36713206)
3. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P et al. (1998). CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188: 1521-1528. (Pubitemid 28489589)
4. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. (2006). Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 296: 177-189. (Pubitemid 44061763)
5. Dai T, Ramirez-Correa G, Gao WD. (2006). Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 553: 222-228. (Pubitemid 44779594)
6. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S et al. (2007). Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13: 3942-3950. (Pubitemid 47037602)
7. Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG et al. (2011). Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res 17: 3134-3145.
8. Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F et al. (2008). Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 103: 432-440.
9. Fujii S, Shimizu K, Kronenberg M, Steinman RM. (2002). Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3: 867-874.
10. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T et al. (2008). Differential function of Tie2 at cell-cell contacts and cellsubstratum contacts regulated by angiopoietin-1. Nat Cell Biol 10: 513-526. (Pubitemid 351627371)
11. Gasparini G, Longo R, Toi M, Ferrara N. (2005). Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2: 562-577. (Pubitemid 41721816)
12. Gerber HP, Ferrara N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680. (Pubitemid 40216420)
13. Gerhardt H, Betsholtz C. (2003). Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314: 15-23. (Pubitemid 37409909)
14. Heath VL, Bicknell R. (2009). Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6: 395-404.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)
16. Jain RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62. (Pubitemid 40093472)
17. June CH, Blazar BR, Riley JL. (2009). Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-716.
18. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. (2000). Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192: 921-930.
19. Kälin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brändli AW. (2007). Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 305: 599-614. (Pubitemid 46686624)
20. Kasai A, Shintani N, Kato H, Matsuda S, Gomi F, Haba R et al. (2008). Retardation of retinal vascular development in apelindeficient mice. Arterioscler Thromb Vasc Biol 28: 1717-1722.
21. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T et al. (2004). Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 325: 395-400. (Pubitemid 39458008)
22. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S et al. (2001). Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 1538: 162-171. (Pubitemid 32402239)
23. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al. (1997). CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629. (Pubitemid 27516282)
24. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N et al. (1999). Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 59: 5102-5105. (Pubitemid 29503967)
25. Kidoya H, Naito H, Takakura N. (2010). Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 115: 3166-3174.
26. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T et al. (2008). Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 27: 522-534. (Pubitemid 351225682)
27. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844. (Pubitemid 23132159)
28. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S et al. (2009). Combination therapy of in vitroexpanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 100: 1092-1098.
29. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. (2007). The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18: 313-325. (Pubitemid 46891288)
30. Lambrecht NW, Yakubov I, Zer C, Sachs G. (2006). Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion. Physiol Genomics 25: 153-165.
31. Lohela M, Bry M, Tammela T, Alitalo K. (2009). VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
32. Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y. (2004). Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 18: 1909-1911. (Pubitemid 39602280)
33. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K et al. (2009). A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182: 2492-2501.
34. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y et al. (2001). TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 97: 2067-2074. (Pubitemid 32239088)
35. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K et al. (2004). Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389. (Pubitemid 38140063)
36. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. (2004). Pathology: cancer cells compress intratumour vessels. Nature 427: 695. (Pubitemid 38294577)
37. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA et al. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474-484; discussion 484-475.
38. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308. (Pubitemid 351430867)
39. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. (2007). Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11: 539-554. (Pubitemid 46856908)
40. Seino K, Fujii S, Harada M, Motohashi S, Nakayama T, Fujisawa T et al. (2005). Valpha14 NKT cell-mediated antitumor responses and their clinical application. Springer Semin Immunopathol 27: 65-74. (Pubitemid 40905063)
41. Shin T, Nakayama T, Akutsu Y, Motohashi S, Shibata Y, Harada M et al. (2001). Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Valpha14 NKT cells. Int J Cancer 91: 523-528. (Pubitemid 32115108)
42. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK et al. (2001). Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 194: 1801-1811. (Pubitemid 34028659)
43. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K et al. (2002). Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99: 1259-1266. (Pubitemid 34547079)
44. Sorhede Winzell M, Magnusson C, Ahren B. (2005). The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 131: 12-17. (Pubitemid 41392985)
45. Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. (2007). Apelin is a potent activator of tumour neoangiogenesis. Oncogene 26: 7692-7699. (Pubitemid 350224216)
46. Spada FM, Koezuka Y, Porcelli SA. (1998). CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188: 1529-1534. (Pubitemid 28489590)
47. Steinman RM, Banchereau J. (2007). Taking dendritic cells into medicine. Nature 449: 419-426. (Pubitemid 47509552)
48. Takakura N, Watanabe T, Suenobu S, Yamada Y, Noda T, Ito Y et al. (2000). A role for hematopoietic stem cells in promoting angiogenesis. Cell 102: 199-209.
49. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. (2003). The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21: 483-513. (Pubitemid 37174539)
50. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX et al. (1998). Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251: 471-476. (Pubitemid 28505047)
51. Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y et al. (2006). Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33: S35-S40. (Pubitemid 44634013)
52. Yamada Y, Takakura N. (2006). Physiological pathway of differentiation of hematopoietic stem cell population into mural cells. J Exp Med 203: 1055-1065.